S.Y. Chui

645 citations
8 papers · 426 · 1 hit paper · h-index 7

Impact in

  • Oncology top 10%
    • Cancer Immunotherapy and Biomarkers
    • HER2/EGFR in Cancer Research
    • Cancer Cells and Metastasis
    • Cancer Genomics and Diagnostics
    • Breast Cancer Treatment Studies

Papers in

S.Y. Chui

8 papers receiving 418 citations

S.Y. Chui's Hit Papers

First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis 2021 · 293 citations
2930+1+3Years since publication50100150200250

Peers

S.Y. Chui
Comparison fields: 5 of 59
  • Oncology 306
  • Cancer Research 110
  • Pulmonary and Respiratory Medicine 132
  • Immunology 79
  • Pediatrics, Perinatology and Child Health 65
Replace Т. Yu. Semiglazova with:
Т. Yu. Semiglazova Russia
Byung Kyun Ko South Korea
Kate Ingarfield United Kingdom
Marcus V. Ortega Alves United States
Thomas M. Deutsch Germany
Gregory A. Durm United States
S. Verma Canada
Catherine A. Bingham United States
Gabriella Del Bene Italy
Elizabeth Charron United States
S.Y. Chui relative to Т. Yu. Semiglazova Russia Т. Yu. Semiglazova's profile →
Citations per field
00.5×3.1×
Т. Yu. Semiglazova · 1×
Citations per year

Countries citing papers authored by S.Y. Chui

Since Specialization
Citations

This map shows the geographic impact of S.Y. Chui's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S.Y. Chui with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S.Y. Chui more than expected).

Fields of papers citing papers by S.Y. Chui

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S.Y. Chui. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S.Y. Chui. The network helps show where S.Y. Chui may publish in the future.

Co-authors

The 25 scholars most cited alongside S.Y. Chui, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with S.Y. Chui Line = papers co-authored together S.Y. Chui links everyone, so they are left out of the graph.

All Works

8 of 8 papers shown
#Work
1
First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis
Hit paper breakdown →
2021293
2 201865
3 202424
4 202014
5 202313
6 20159
7 20167
8 20111

About S.Y. Chui

S.Y. Chui is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Clinical Psychology, Molecular Biology and Social Psychology, having authored 8 papers that have together received 426 indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (4 papers), Advanced Breast Cancer Therapies (3 papers), Advanced biosensing and bioanalysis techniques (1 paper), Breast Cancer Treatment Studies (1 paper), Prostate Cancer Treatment and Research (1 paper), Lipid Membrane Structure and Behavior (1 paper), Economic and Financial Impacts of Cancer (1 paper) and Healthcare professionals’ stress and burnout (1 paper). The work is most often cited by research in Oncology (306 citations), Cancer Research (110 citations), Pulmonary and Respiratory Medicine (132 citations), Immunology (79 citations) and Pediatrics, Perinatology and Child Health (65 citations). S.Y. Chui has collaborated with scholars based in United States, Germany and Japan. Frequent co-authors include Hiroji Iwata, Luciana Molinero, Sylvia Adams, Andreas Schneeweiß, Shilpen Patel, Carlos H. Barrios, Sherene Loi, Eric P. Winer, Manika Kaul and P. Schmid. Their work appears in journals such as Annals of Oncology, International Journal of Nursing Studies, Nature Chemistry, Journal of Clinical Oncology and ESMO Open.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact